A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
This study will evaluate the evolution of leptomeningeal lesions via leptomeningeal contrast enhancement (LMCE) presence/disappearance after treatment administration in patients with active progressive multiple sclerosis (MS). In addition, this study will investigate if the presence of leptomeningeal inflammation is associated with alterations of B cell repertoire and whether therapy with ocrelizumab will lead to change of B cell repertoire in LMCE-positive patients.
Epistemonikos ID: 1cf60d8b465d00b67dfcc7d1d54a75fdee55028c
First added on: May 10, 2024